Authors
Hruslov M.V.2, Stojko Yu.M.1, Zamyatin M.N.1
1 Federal State Public Institution «National Medical and Surgical Center named after N.I. Pirogov» of the Ministry of Healthcare of the Russian Federation
2 BMU «Kursk regional clinical hospital», Kursk
Abstract
Purpose of the work. Analysis of different approaches to organize INR monitoring of patients with high risk of venous thromboembolism recurrence.
Materials and methods. One group of patients (84 people) were observed by physicians in hospital in the district clinics; the second group of patients (132) were observed specialists in the system of distant monitoring of INR. Term follow-up was 2 years. We evaluated time of patient’s staying in therapeutic range of INR, the frequency of recurrence of deep vein thrombosis, thromboembolic and hemorrhagic complications.
Results. Аverage time of patient’s staying in therapeutic range of INR for patients of the first group was 34.5%, in the second group 71.2%. In the first group of patients there were significantly more episodes of recurrence of thrombosis – 5 (5.95%) vs. 1 (0.76%) in the second group. There were significantly more minor bleedings in the first group of patients – 11 (13.09%) compared to 6 (4.54%).
Conclusion. Тhe system of distant monitoring of INR is an effective method of organization of secondary prevention of thromboembolic complications in patients. It allows to significantly increase the effectiveness and safety of treatment of vitamin K antagonists, regardless of the remoteness of the patient from the medical institution.
Keywords: system of distant monitoring, vitamin K antagonist, deep vein thrombosis, PE, prevention of recurrent thrombosis, warfarin.
References
1. Rossijskie klinicheskie rekomendacii po diagnostike, lecheniyu i profilaktike venoznyh tromboembolicheskih oslozhnenij (VTEO) // Flebologiya. 2015. № 2. Vyp. 2. (In Russ).
2. SHubik YUV. Varfarin i ego mesto v profilaktike tromboembolij pri fibrillyacii predserdij. Medicinskij sovet. – 2015: 38–43. (In Russ).
3. Gilyarov MYU, Konstantinova EV. Peroral’nye antikoagulyanty lechenii venoznyh tromboembolicheskih oslozhnenij. Medicinskij sovet. – 2017: 56–62. (In Russ).
4. Holbrook A, Schulman S, Witt DM. et al. Evidence-Based Management of Anticoagulant Therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. – 2012, 141(Suppl): e152S-e184S.
5. Rosendaal FR, Cannegieter SC, van der Meer FJM. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. –1993; 39: 236–239
6. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH. Risk factors fоr complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Groop. Ann Intern Med. – 1993;118(7): 511–520.
7. Gallagher AM, Setakis E, Plumb JM. et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients // ThrombHaemost. – 2011. Vol. 106(5). P. 968–977. doi: 10.1160/TH11-05-0353.
8. Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do? / Lader E, Martin N, Cohen G. et al. // J. Clin. Pharm. Ther. – 2012. – Vol. 37, № 4. – Р. 375–377.
9. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control. Result from SPORTIF III and IV / White H, Gruber M, Feyzi J et al. // Arch. Intern. med. – 2007. – Vol. 167. – Р. 239–245.
10. Haas S, ten Cate H, Accetta G, Angchaisuksiri P, Bassand J-P, Camm AJ, et al. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS ONE. – 2016;11(10): e0164076. doi: 10.1371/journal.pone.0164076.
